clinical trial · NCT07515014
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Eisai Co., Ltd.·phase2·recruiting·n = 256
Systemic Lupus ErythematosusE6742Placebo
brief summary
The main purpose of the study is to demonstrate the efficacy based on dose response of E6742 compared with placebo as defined by the proportion of participants achieving a response using the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) with a low dose of oral corticosteroids (OCS) (prednisone or equivalent) at Week 24 in participants with systemic lupus erythematosus (SLE).
started
Mar 31, 2026
primary completion
Aug 5, 2028
completion
Mar 1, 2029
last updated
Jul 2, 2026
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Response Study to Evaluate the Efficacy and Safety of E6742 in Subjects With Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol